<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Pharmacology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1663-9812</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7298068</article-id>
    <article-id pub-id-type="doi">10.3389/fphar.2020.00875</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Pharmacology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>OSlihc: An Online Prognostic Biomarker Analysis Tool for Hepatocellular Carcinoma</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>An</surname>
          <given-names>Yang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn003">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/743108"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Qiang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn003">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/647946"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Guosen</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/695335"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sun</surname>
          <given-names>Fengjie</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/996299"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Lu</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/702101"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Haojie</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/995653"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Yingkun</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/995684"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Peng</surname>
          <given-names>Yanyu</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/995690"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Wan</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/677026"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ji</surname>
          <given-names>Shaoping</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/651503"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Xiangqian</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn001">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/605469"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>Department of Predictive Medicine, Institute of Biomedical Informatics, Cell Signal Transduction Laboratory, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Kaifeng Key Laboratory of Cell Signal Transduction, School of Basic Medical Sciences, School of Software, Henan University</institution>, <addr-line>Kaifeng</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Department of Anesthesia, Stanford University</institution>, <addr-line>Stanford, CA</addr-line>, <country>United States</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Jean Paul Deslypere, Aesculape CRO Singapore and Belsele, Belgium</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Zijian Zhang, Baylor College of Medicine, United States; Chengqi Xu, Huazhong University of Science and Technology, China</p>
      </fn>
      <corresp id="fn001">*Correspondence: Xiangqian Guo, <email xlink:href="mailto:xqguo@henu.edu.cn" xlink:type="simple">xqguo@henu.edu.cn</email></corresp>
      <fn fn-type="other" id="fn002">
        <p>This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology</p>
      </fn>
      <fn fn-type="equal" id="fn003">
        <p>†These authors have contributed equally to this work</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>10</day>
      <month>6</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>11</volume>
    <elocation-id>875</elocation-id>
    <history>
      <date date-type="received">
        <day>12</day>
        <month>1</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>27</day>
        <month>5</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2020 An, Wang, Zhang, Sun, Zhang, Li, Li, Peng, Zhu, Ji and Guo</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder>An, Wang, Zhang, Sun, Zhang, Li, Li, Peng, Zhu, Ji and Guo</copyright-holder>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Liver hepatocellular carcinoma (LIHC) is one of the most common malignant tumors in the world with an increasing number of fatalities. Identification of novel prognosis biomarker for LIHC may improve treatment and therefore patient outcomes. The availability of public gene expression profiling data offers the opportunity to discover prognosis biomarkers for LIHC. We developed an online consensus survival analysis tool named OSlihc using gene expression profiling and long-term follow-up data to identify new prognosis biomarkers. OSlihc consists of 637 cases from four independent cohorts. As a risk assessment tool, OSlihc generates the Kaplan–Meier survival plot with hazard ratio (HR) and p value to evaluate the prognostic value of a gene of interest. To test the reliability of OSlihc, we analyzed 65 previous reported prognostic biomarkers in OSlihc and showed that all of which have significant prognostic values. Furthermore, we identified four novel potential prognostic biomarkers (<italic>ATG9A</italic>, <italic>WIPI1</italic>, <italic>CXCL1</italic>, and <italic>CSNK2A2</italic>) for LIHC, the elevated expression of which predict the unfavorable survival outcomes. These genes (<italic>ATG9A</italic>, <italic>WIPI1</italic>, <italic>CXCL1</italic>, and <italic>CSNK2A2</italic>) may be potentially new biomarkers to identify at-risk LIHC patients when further validated. By OSlihc, users can evaluate the prognostic abilities of genes of their interest, which provides a platform for researchers to identify prognostic biomarkers to further develop targeted therapy strategies for LIHC patients. OSlihc is public and free to the users at <uri xlink:type="simple" xlink:href="http://bioinfo.henu.edu.cn/LIHC/LIHCList.jsp">http://bioinfo.henu.edu.cn/LIHC/LIHCList.jsp</uri>.</p>
    </abstract>
    <kwd-group>
      <kwd>liver hepatocellular carcinoma</kwd>
      <kwd>prognosis biomarker</kwd>
      <kwd>survival analysis</kwd>
      <kwd>gene expression profiling</kwd>
      <kwd>survival outcome</kwd>
    </kwd-group>
    <counts>
      <fig-count count="5"/>
      <table-count count="3"/>
      <equation-count count="0"/>
      <ref-count count="30"/>
      <page-count count="9"/>
      <word-count count="3041"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>As one of the most common tumors, hepatocellular carcinoma (HCC) also known as liver hepatocellular carcinoma (LIHC), is a leading cause of death of cancer globally (<xref rid="B27" ref-type="bibr">Yu et al., 2010</xref>; <xref rid="B17" ref-type="bibr">Pinato et al., 2014</xref>; <xref rid="B3" ref-type="bibr">Cristea et al., 2015</xref>). A number of staging and grading systems have been commonly used for LIHC, including TNM, Barcelona Clinic Liver Cancer (BCLC), albumin-bilirubin (ALBI) grading, and Okuda system (<xref rid="B19" ref-type="bibr">Selcuk, 2017</xref>). For LIHC patients, surgical excision is an optimal treatment (<xref rid="B14" ref-type="bibr">Mullath and Krishna, 2019</xref>). However, the majority of LIHC patients have the risks of recurrence and metastasis, leading to a much lower 5 years survival (<xref rid="B1" ref-type="bibr">Buonaguro et al., 2015</xref>). To improve patients’ quality of life, treatment should be tailored according to more accurate predicted disease outcome (<xref rid="B17" ref-type="bibr">Pinato et al., 2014</xref>). So far, some biomarkers have been identified to provide insights of disease outcomes. For example, α-fetoprotein (AFP) and des-gamma-carboxy-prothrombin (DCP), PCNA and Ki-67 are the most frequently used biomarkers for LIHC (<xref rid="B7" ref-type="bibr">King et al., 1998</xref>; <xref rid="B9" ref-type="bibr">Lee et al., 2013</xref>; <xref rid="B11" ref-type="bibr">Lin et al., 2015</xref>; <xref rid="B10" ref-type="bibr">Lee et al., 2016</xref>; <xref rid="B13" ref-type="bibr">Ma et al., 2016</xref>; <xref rid="B26" ref-type="bibr">Yao et al., 2016</xref>). However, due to the high heterogeneity of LIHC, more prognosis biomarkers for LIHC need to be discovered.</p>
    <p>In the present study, we developed an easy-to-use web server named OSlihc, to provide an online platform to evaluate potential prognostic biomarkers for LIHC in multiple independent cohorts. In addition, we have validated the prognostic ability of 65 previously reported biomarkers using this web tool, and have identified four novel potential prognostic biomarkers for LIHC, including <italic>ATG9A</italic>, <italic>WIPI1</italic>, <italic>CXCL1</italic>, and <italic>CSNK2A2</italic>. By using OSlihc, researchers and clinicians can expediently evaluate the prognostic value of the genes of their interests.</p>
  </sec>
  <sec id="s2">
    <title>Methods</title>
    <sec id="s2_1">
      <title>Data Collection and Processing</title>
      <p>Gene expression profiling data and clinical follow-up information of hepatocellular carcinoma were collected from TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus) database. For TCGA dataset, gene expression profiling (RNA-seq, level-3, HiSeqV2) and follow-up data (361 cases) were downloaded in 2018 (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). For GEO datasets, the keywords, including “hepatocellular carcinoma”, “gene expression” and “survival” were used to search in GEO database. Then the datasets containing mRNA expression and survival data with at least 50 cases were included. As a result, three GEO datasets (GSE76427, GSE20140, and GSE27150) with 115, 80, and 81 clinical LIHC cases, respectively (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>), were collected.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Summary of datasets in OSlihc.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">Dataset</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Sample size</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Data type</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Platform</th>
              <th valign="top" align="center" rowspan="1" colspan="1">No. of death</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Median of OS (months)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Survival terms</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">TCGA</td>
              <td valign="top" align="center" rowspan="1" colspan="1">361</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RNA-seq</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Illumina HiSeqV2</td>
              <td valign="top" align="center" rowspan="1" colspan="1">129</td>
              <td valign="top" align="center" rowspan="1" colspan="1">20.03</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS, DSS, DFI, PFI</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE76427</td>
              <td valign="top" align="center" rowspan="1" colspan="1">115</td>
              <td valign="top" align="left" rowspan="1" colspan="1">cDNA array</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL10558</td>
              <td valign="top" align="center" rowspan="1" colspan="1">23</td>
              <td valign="top" align="center" rowspan="1" colspan="1">13.92</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS, RFS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE20140</td>
              <td valign="top" align="center" rowspan="1" colspan="1">80</td>
              <td valign="top" align="left" rowspan="1" colspan="1">cDNA array</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL5474</td>
              <td valign="top" align="center" rowspan="1" colspan="1">32</td>
              <td valign="top" align="center" rowspan="1" colspan="1">96.15</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE27150</td>
              <td valign="top" align="center" rowspan="1" colspan="1">81</td>
              <td valign="top" align="left" rowspan="1" colspan="1">cDNA array</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL13128</td>
              <td valign="top" align="center" rowspan="1" colspan="1">28</td>
              <td valign="top" align="center" rowspan="1" colspan="1">39</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Total</td>
              <td valign="top" align="center" rowspan="1" colspan="1">637</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">212</td>
              <td valign="top" align="center" rowspan="1" colspan="1">22.43</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Five clinical survival terms, including OS (overall survival), DSS (disease-specific survival), RFS (relapse free survival), DFI (disease-free interval), and PFI (progression-free interval) (<xref rid="B12" ref-type="bibr">Liu et al., 2018</xref>), were used in OSlihc web server (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). The clinicopathologic characteristics of LIHC patients in OSlihc database are summarized in <xref ref-type="supplementary-material" rid="ST1"><bold>Tables S1</bold></xref> and <xref ref-type="supplementary-material" rid="ST2"><bold>S2</bold></xref>.</p>
    </sec>
    <sec id="s2_2">
      <title>Development of OSlihc</title>
      <p>OSlihc includes two major assemblies: data storage and analysis. The OSlihc web server is hosted in a tomcat 7.0 server in Windows 2008 system, the web interface is developed by HTML and JSP languages, the controlling part is developed by Servlet, and the database is handled by SQL Server which stores and manages the gene expression profiling and clinical data. The Servlet acts as a connecting layer between the frontend and the backend to provide interaction to users. Moreover, OSlihc web server is operated by R and Java, which manipulates the request from users and then returns the analysis results to users, the R package “Rserve” acts as a connecting layer between R and Java. The JDBC package serves as the connection middleware between R, Java, and SQL. In addition, the R package “survival” generates Kaplan–Meier survival curves and calculates hazard ratio with 95% confidence intervals and <italic>p</italic> value. System architecture flow diagram is presented in <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>, as previous described (<xref rid="B22" ref-type="bibr">Wang et al., 2019a</xref>; <xref rid="B23" ref-type="bibr">Wang et al., 2019b</xref>; <xref rid="B24" ref-type="bibr">Xie et al., 2019</xref>; <xref rid="B28" ref-type="bibr">Zhang et al., 2019</xref>). OSlihc is available at <uri xlink:type="simple" xlink:href="http://bioinfo.henu.edu.cn/LIHC/LIHCList.jsp">http://bioinfo.henu.edu.cn/LIHC/LIHCList.jsp</uri>.</p>
      <fig id="f1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Flowchart of web server architecture.</p>
        </caption>
        <graphic xlink:href="fphar-11-00875-g001"/>
      </fig>
    </sec>
    <sec id="s2_3">
      <title>Validation of Prognostic Biomarkers in OSlihc</title>
      <p>To assess the performance and reliability of prognostic analysis of OSlihc web server, previously reported prognostic biomarkers for LIHC were searched in PubMed using the keywords “hepatocellular carcinoma”, “survival”, “prognosis”, and “biomarker”. As a result, we collected 67 papers with 65 reported prognostic biomarkers. The prognostic capabilities of these reported prognostic genes were evaluated by plotting the survival curve in OSlihc. We input gene symbols of the 65 reported prognostic biomarkers into the “Gene symbol” box individually, and then clicked the “Kaplan–Meier plot” button to obtain the survival curve plot. We listed “clinical survival terms”, “cut-off”, “case”, “p value”, “HR”, “95%CI”, “detection level”, and “validation”, and compared the “prognostic outcome” between “In OSlihc” and “In reference” when the reported prognostic gene exhibited the higher expression level.</p>
    </sec>
    <sec id="s2_4">
      <title>Identification of Novel Potential Prognostic Biomarkers in OSlihc</title>
      <p>To identify prognostic biomarker candidates for LIHC, we genome-widely evaluated the prognostic values of human genes for each dataset using Cox regression analysis. Genes significantly related to prognosis were selected from each dataset (cox p value &lt; 0.05). Then these genes were overlapped among the four datasets, as a result, four genes were identified as potential prognostic biomarkers for they were significantly related to prognosis in three datasets, including <italic>ATG9A</italic>, <italic>WIPI1</italic>, <italic>CXCL1</italic>, and <italic>CSNK2A2</italic>.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec id="s3_1">
      <title>Clinicopathologic Characteristics of LIHC Patients in OSlihc</title>
      <p>In the TCGA cohort, the median age of a total of 361 LIHC patients was 61. When examining the disease stages of LIHC patients, stage I patients accounts for 46% of all the LIHC patients (n=167), stage II accounts for 23% (n=82), stage III accounts for 23% (n=84), and stage IV accounts for 1% (n=4) (<xref ref-type="supplementary-material" rid="ST1"><bold>Table S1</bold></xref>). In the GSE76427 cohort, the median age of a total of 115 patients was 64, and the distribution of BCLC stage was that stage A accounts for 64% (n=74), stage B accounts for 24% (n=28), stage C accounts for 8% (n=9), and stage 0 accounts for 3% (n=4) (<xref ref-type="supplementary-material" rid="ST2"><bold>Table S2</bold></xref>). In the GSE20140 cohort, microvascular invasion was present in 21% (n=17) of LIHC patients, and absent in 56% (n=45) of LIHC patients (<xref ref-type="supplementary-material" rid="ST2"><bold>Table S2</bold></xref>). The clinicopathologic information of GSE27150 dataset were unavailable. The median OS time is 22.43 months of all LIHC patients in OSlihc (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>). The summaries of clinicopathologic characteristics of each cohort were presented in <xref ref-type="supplementary-material" rid="ST1"><bold>Tables S1</bold></xref> and <xref ref-type="supplementary-material" rid="ST2"><bold>S2</bold></xref>. The Kaplan–Meier plots for LIHC patients in OSlihc stratified by different pathologic stage and BCLC stage were presented in <xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>. The pathologic stage and BCLC stage were significantly associated with OS (<italic>p</italic>&lt;0.0001 and <italic>p</italic>=0.013, respectively) (<xref ref-type="fig" rid="f2"><bold>Figures 2A, B</bold></xref>). And the serum AFP level was also significantly associated with OS (<italic>p</italic>=0.02) (<xref ref-type="fig" rid="f2"><bold>Figure 2C</bold></xref>).</p>
      <fig id="f2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Survival analysis of clinical characteristics of the patients included in OSlihc. <bold>(A)</bold> Pathologic stage, <bold>(B)</bold> BCLC stage, <bold>(C)</bold> Serum AFP level.</p>
        </caption>
        <graphic xlink:href="fphar-11-00875-g002"/>
      </fig>
    </sec>
    <sec id="s3_2">
      <title>Application of OSlihc</title>
      <p>OSlihc has the ability of drawing a forest plot for all the cohorts to highlight the prognostic significance of interested genes (cutoff: upper 50% vs. lower 50%). In OSlihc, “Gene symbol”, “Data Source”, “Survival”, and “Split patients by” are the four main parameters to evaluate the prognostic value of a gene of interest in LIHC (<xref ref-type="fig" rid="f3"><bold>Figure 3A</bold></xref>). In general, the official gene symbol is required in the “Gene symbol” box by the users. A red warning message would be shown if the input was not an official gene symbol (<xref ref-type="fig" rid="f3"><bold>Figure 3B</bold></xref>). Drop-down menu of “Data source” provides five options for users to take each of the four individual cohorts (TCGA, GSE76427, GSE20140, and GSE27150 datasets) or a combined cohort pooling all four above mentioned cohorts into one for survival analysis (<xref ref-type="fig" rid="f3"><bold>Figure 3C</bold></xref>). The combined cohort denotes that each cohort was individually stratified into subgroups by choosing a cutoff value for gene expression level, which were then pooled together for prognosis analysis. As a result, users have the choice to assess the prognostic value of a candidate gene in a single or the combined cohort according to the needs. In OSlihc, five survival terms could be generated, including OS, DSS, RFS, DFI, and PFI. OS could be measured in all the cohorts and in combined cohort, while RFS could be calculated only in GSE76427, DSS, DFI, and PFI could be analyzed only in the TCGA cohort (<xref ref-type="fig" rid="f3"><bold>Figures 3D, E</bold></xref>). “Split patients by” option could categorize LIHC patients into 2–4 subgroups by the expression level of the inputted gene (such as Upper or Lower 25%, 30%, 50%), users can select the different cutoff values (<xref ref-type="fig" rid="f3"><bold>Figure 3F</bold></xref>).</p>
      <fig id="f3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Overview of OSlihc. <bold>(A)</bold> Screenshot of OSlihc main interface. <bold>(B–F)</bold> Input and output interface of OSlihc.</p>
        </caption>
        <graphic xlink:href="fphar-11-00875-g003"/>
      </fig>
      <p>In addition, additional multiple optional parameters could also be set as confounding clinical factors to sub-categorize LIHC patients for users to choose, including “Gender”, “BCLC Stage”, “TNM”, “Grade”, “Alcohol”, “Race”, etc. (<xref ref-type="supplementary-material" rid="SF1"><bold>Figure S1</bold></xref>). Take “BCLC Stage” (on the interface of GSE76427 cohort) for example, users can select BCLC Stage (All, A, B, C, or 0) of LIHC from the drop-down menu box in OSlihc to evaluate the BCLC Stage-specific prognostic value of putative genes (<xref ref-type="supplementary-material" rid="SF1"><bold>Figure S1C</bold></xref>). When all the options have been set, user could click the “Kaplan–Meier plot” button, OSlihc will receive the user’s request and return the prognosis analysis results for the inputted gene to users on the output web page, which graphically displays the Kaplan–Meier survival curve with p value and HR (with 95% confidence interval).</p>
    </sec>
    <sec id="s3_3">
      <title>Validation of Previously Reported LIHC Prognostic Biomarkers in OSlihc</title>
      <p>In order to assess the reliability and capability of OSlihc web server in performing prognosis analysis, we collected 65 previously reported prognostic biomarkers at protein, mRNA or serum levels from 67 literatures. CDK1, HDAC2, RORA, FOXO3, and PCNA were among these 65 genes to be evaluated in OSlihc. The analysis results showed that all the 65 previously reported prognostic biomarkers have been demonstrated significant prognostic abilities (not only OS, but also DSS, DFI, and PFI) in OSlihc web server (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref> and <xref ref-type="supplementary-material" rid="ST3"><bold>Table S3</bold></xref>). As previously described (<xref rid="B16" ref-type="bibr">Ouyang et al., 2016</xref>), <italic>SPP1</italic>, <italic>MKI67</italic>, and <italic>BIRC5</italic> genes are significantly correlated with survival (OS, DSS, DFI, and PFI) in OSlihc (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref>, <xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>, and <xref ref-type="supplementary-material" rid="SF2"><bold>Figure S2</bold></xref>). Patients with higher <italic>SPP1</italic>, <italic>MKI67</italic>, or <italic>BIRC5</italic> expression have shorter survival (<italic>p</italic>&lt;0.0001, <italic>p</italic>=6e-04 or 4e-04, respectively), while patients with lower <italic>SPP1</italic>, <italic>MKI67</italic>, or <italic>BIRC5</italic> expression exhibited longer survival (<xref rid="T2" ref-type="table"><bold>Table 2</bold></xref> and <xref ref-type="fig" rid="f4"><bold>Figure 4</bold></xref>). When compared with normal tissue, <italic>SPP1</italic>, <italic>MKI67</italic>, or <italic>BIRC5</italic> expression was significantly increased in LIHC tissues (<xref ref-type="supplementary-material" rid="SF3"><bold>Figure S3</bold></xref>).</p>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Validation of previously published prognostic biomarkers for LIHC in OSlihc.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" rowspan="2" align="left" colspan="1">Gene symbol</th>
              <th valign="top" rowspan="2" align="center" colspan="1">Biomarker name</th>
              <th valign="top" rowspan="2" align="center" colspan="1">Clinical survival terms</th>
              <th valign="top" colspan="5" align="center" rowspan="1">In OSlihc</th>
              <th valign="top" colspan="5" align="center" rowspan="1">In reference</th>
              <th valign="top" rowspan="2" align="center" colspan="1">Prognostic outcome (higher expression)</th>
              <th valign="top" rowspan="2" align="center" colspan="1">Ref.</th>
            </tr>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">Cut-off</th>
              <th valign="top" align="center" rowspan="1" colspan="1">p value</th>
              <th valign="top" align="center" rowspan="1" colspan="1">HR</th>
              <th valign="top" align="center" rowspan="1" colspan="1">95%CI</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Case</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Cut-off</th>
              <th valign="top" align="center" rowspan="1" colspan="1">p value</th>
              <th valign="top" align="center" rowspan="1" colspan="1">case</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Detection level</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Validation</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" rowspan="4" align="left" colspan="1">SPP1</td>
              <td valign="top" rowspan="4" align="left" colspan="1">Osteopontin (OPN)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
              <td valign="top" rowspan="4" align="center" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.3521</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6394-3.3747</td>
              <td valign="top" rowspan="4" align="center" colspan="1">361</td>
              <td valign="top" rowspan="4" align="center" colspan="1">/</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05</td>
              <td valign="top" rowspan="4" align="center" colspan="1">110</td>
              <td valign="top" rowspan="4" align="left" colspan="1">serum</td>
              <td valign="top" rowspan="4" align="left" colspan="1">Yes, serum biochemical assay</td>
              <td valign="top" rowspan="1" align="center" colspan="1">worse</td>
              <td valign="top" rowspan="1" align="center" colspan="1">(<xref rid="B25" ref-type="bibr">Yang et al., 2008</xref>; <xref rid="B6" ref-type="bibr">Jin et al., 2014</xref>; <xref rid="B18" ref-type="bibr">Qin, 2014</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DSS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0126</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.8422</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.1403-2.9763</td>
              <td valign="top" align="center" rowspan="1" colspan="1">/</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DFI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0183</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.071-2.1008</td>
              <td valign="top" align="center" rowspan="1" colspan="1">DFS: p &lt; 0.05</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PFI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0078</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5611</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.1242-2.1679</td>
              <td valign="top" align="center" rowspan="1" colspan="1">/</td>
            </tr>
            <tr>
              <td valign="top" rowspan="4" align="left" colspan="1">BIRC5</td>
              <td valign="top" rowspan="4" align="left" colspan="1">Survivin</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
              <td valign="top" rowspan="4" align="center" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">4e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.9443</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.3457-2.8093</td>
              <td valign="top" rowspan="4" align="center" colspan="1">361</td>
              <td valign="top" rowspan="4" align="center" colspan="1">upper n = 31/lower n = 41</td>
              <td valign="top" align="center" rowspan="1" colspan="1">/</td>
              <td valign="top" rowspan="4" align="center" colspan="1">72</td>
              <td valign="top" rowspan="4" align="left" colspan="1">protein</td>
              <td valign="top" rowspan="4" align="left" colspan="1">Yes, IHC assay</td>
              <td valign="top" rowspan="1" align="center" colspan="1">worse</td>
              <td valign="top" rowspan="1" align="center" colspan="1">(<xref rid="B5" ref-type="bibr">Fields et al., 2004</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DSS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.4062</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5199-3.8095</td>
              <td valign="top" align="center" rowspan="1" colspan="1">/</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DFI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">9e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.753</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.2585-2.4419</td>
              <td valign="top" align="center" rowspan="1" colspan="1">DFS: 0.0098</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PFI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0012</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.7165</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.2375-2.3809</td>
              <td valign="top" align="center" rowspan="1" colspan="1">/</td>
            </tr>
            <tr>
              <td valign="top" rowspan="4" align="left" colspan="1">MKI67</td>
              <td valign="top" rowspan="4" align="left" colspan="1">Ki-67</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
              <td valign="top" rowspan="1" align="center" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">6e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.9063</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.3174-2.7586</td>
              <td valign="top" rowspan="4" align="center" colspan="1">361</td>
              <td valign="top" rowspan="4" align="center" colspan="1">upper n = 47/lower n = 0</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0009</td>
              <td valign="top" rowspan="4" align="center" colspan="1">67</td>
              <td valign="top" rowspan="4" align="left" colspan="1">protein (Ki-67 labeling index &gt;10% indicated poor prognosis)</td>
              <td valign="top" rowspan="4" align="left" colspan="1">Yes, IHC assay</td>
              <td valign="top" rowspan="1" align="center" colspan="1">worse</td>
              <td valign="top" rowspan="1" align="center" colspan="1">(<xref rid="B7" ref-type="bibr">King et al., 1998</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DSS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0011</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">2.1783</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.3664-3.4729</td>
              <td valign="top" align="center" rowspan="1" colspan="1">/</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DFI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.002</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6821</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.2089-2.3404</td>
              <td valign="top" align="center" rowspan="1" colspan="1">DFS: 0.02</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PFI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0027</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6475</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.1891-2.2827</td>
              <td valign="top" align="center" rowspan="1" colspan="1">/</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="f4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Validation of the top three high-frequency reported biomarkers in OSlihc. Kaplan–Meier plots for <bold>(A)</bold>
<italic>SPP1</italic>, <bold>(B)</bold>
<italic>MKI67</italic>, and <bold>(C)</bold>
<italic>BIRC5</italic> in terms of OS. <italic>p</italic>-value, confidence interval (95%CI) and number at risk are as shown. The y-axis represents survival rate and the x-axis represents survival time (months). <italic>p</italic> = 0 denotes <italic>p</italic> &lt; 0.0001.</p>
        </caption>
        <graphic xlink:href="fphar-11-00875-g004"/>
      </fig>
    </sec>
    <sec id="s3_4">
      <title>Identification of Novel Potential LIHC Prognostic Biomarkers in OSlihc</title>
      <p>To identify new prognostic biomarker candidates for LIHC, we genome-widely evaluated the prognostic values of human genes using Cox regression analysis, and identified four genes which show significant association with survival in OSlihc, and these four genes including <italic>ATG9A</italic> (<xref rid="B20" ref-type="bibr">Tang et al., 2013</xref>), <italic>WIPI1</italic> (<xref rid="B4" ref-type="bibr">D’Arcangelo et al., 2018</xref>), <italic>CXCL1</italic> (<xref rid="B30" ref-type="bibr">Zou et al., 2014</xref>; <xref rid="B8" ref-type="bibr">le Rolle et al., 2015</xref>; <xref rid="B15" ref-type="bibr">Nakashima et al., 2015</xref>; <xref rid="B21" ref-type="bibr">Wang et al., 2016</xref>; <xref rid="B2" ref-type="bibr">Cabrero-de Las Heras and Martinez-Balibrea, 2018</xref>; <xref rid="B29" ref-type="bibr">Zhuo et al., 2018</xref>), and <italic>CSNK2A2</italic> have not been reported to exhibit the prognostic values in LIHC up to now and were subject to the prognosis analysis in OSlihc (<xref ref-type="supplementary-material" rid="ST4"><bold>Table S4</bold></xref>). Notably, all these four genes exhibited good performance in predicting LIHC patient outcome (<xref rid="T3" ref-type="table"><bold>Table 3</bold></xref> and <xref ref-type="fig" rid="f5"><bold>Figure 5</bold></xref>). Moreover, we found that patients with higher <italic>ATG9A</italic>, <italic>WIPI1</italic>, <italic>CXCL1</italic>, or <italic>CSNK2A2</italic> expression have the worst survival rate (<xref ref-type="fig" rid="f5"><bold>Figure 5</bold></xref>), indicating that the elevated expression of all these potential predictors could predict the unfavorable prognosis.</p>
      <table-wrap id="T3" position="float">
        <label>Table 3</label>
        <caption>
          <p>Evaluation of novel potential prognostic biomarkers for LIHC in OSlihc.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" rowspan="2" align="left" colspan="1">Gene symbol</th>
              <th valign="top" colspan="5" align="center" rowspan="1">In OSlihc</th>
              <th valign="top" rowspan="2" align="center" colspan="1">case</th>
            </tr>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">cut-off</th>
              <th valign="top" align="center" rowspan="1" colspan="1">survival terms</th>
              <th valign="top" align="center" rowspan="1" colspan="1">p value</th>
              <th valign="top" align="center" rowspan="1" colspan="1">HR</th>
              <th valign="top" align="center" rowspan="1" colspan="1">95%CI</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" rowspan="5" align="left" colspan="1">ATG9A</td>
              <td valign="top" rowspan="5" align="center" colspan="1">upper 30%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0157</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4513</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0727–1.9633</td>
              <td valign="top" align="center" rowspan="1" colspan="1">556</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0012</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.7919</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.2594–2.5496</td>
              <td valign="top" rowspan="4" align="center" colspan="1">361</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DSS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0246</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6859</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0693–2.6581</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DFI</td>
              <td valign="top" colspan="3" align="center" rowspan="1">no significance</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PFI</td>
              <td valign="top" colspan="3" align="center" rowspan="1">no significance</td>
            </tr>
            <tr>
              <td valign="top" rowspan="5" align="left" colspan="1">WIPI1</td>
              <td valign="top" rowspan="5" align="center" colspan="1">upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.9141</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4027–2.6119</td>
              <td valign="top" align="center" rowspan="1" colspan="1">556</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0176</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5866</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0837–2.323</td>
              <td valign="top" rowspan="4" align="center" colspan="1">361</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DSS</td>
              <td valign="top" colspan="3" align="center" rowspan="1">no significance</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DFI</td>
              <td valign="top" colspan="3" align="center" rowspan="1">no significance</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PFI</td>
              <td valign="top" colspan="3" align="center" rowspan="1">no significance</td>
            </tr>
            <tr>
              <td valign="top" rowspan="5" align="left" colspan="1">CXCL1</td>
              <td valign="top" rowspan="5" align="center" colspan="1">upper 30%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
              <td valign="top" colspan="3" align="center" rowspan="1">no significance</td>
              <td valign="top" align="center" rowspan="1" colspan="1">636</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0081</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6312</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.1356–2.3432</td>
              <td valign="top" rowspan="4" align="center" colspan="1">361</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DSS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0454</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6077</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0098–2.5595</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DFI</td>
              <td valign="top" colspan="3" align="center" rowspan="1">no significance</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PFI</td>
              <td valign="top" colspan="3" align="center" rowspan="1">no significance</td>
            </tr>
            <tr>
              <td valign="top" rowspan="5" align="left" colspan="1">CSNK2A2</td>
              <td valign="top" rowspan="5" align="center" colspan="1">upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">5e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.7411</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.2721–2.383</td>
              <td valign="top" align="center" rowspan="1" colspan="1">556</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0348</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5271</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0308–2.2623</td>
              <td valign="top" rowspan="4" align="center" colspan="1">361</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DSS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0197</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.7965</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0979–2.9396</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">DFI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0208</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4965</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0631–2.1065</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PFI</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0254</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4692</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0485–2.0586</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="f5" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Evaluation of the prognostic values of potential biomarkers in OSlihc. Kaplan–Meier plots for high (red) and low (green) <italic>ATG9A</italic>, <italic>WIPI1</italic>, <italic>CXCL1</italic>, or <italic>CSNK2A2</italic>-expression cohort in combined dataset <bold>(A, C</bold>, <bold>F)</bold> and TCGA dataset <bold>(B, D, E</bold>, <bold>G)</bold>. <italic>p</italic>-value, confidence interval (95%CI) and number at risk are as shown. The y-axis represents survival rate and the x-axis represents survival time (months).</p>
        </caption>
        <graphic xlink:href="fphar-11-00875-g005"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>LIHC is a leading malignant tumor worldwide with high metastasis and recurrence rate. Due to the complex molecular heterogeneity and poor prognosis of LIHC, it is urgent to develop biomarkers for LIHC prognosis. In the present study, we established a web server OSlihc using gene expression profiling and long-term clinical follow-up data. This prognosis analysis web server aims to assess the association between candidate gene and survival by an easy and interactive way. In current study, we have validated the association between survival and 65 previously published biomarkers for LIHC in our OSlihc server. As examples, three frequently-used biomarkers in LIHC, Osteopontin (OPN) (encoded by <italic>SPP1</italic> gene), Survivin (encoded by <italic>BIRC5</italic> gene) and Ki-67 (encoded by <italic>MKI67</italic> gene), showed prognostic abilities in OSlihc, and the elevated expression of these genes predicted the unfavorable prognosis, consistent with previous reports (<xref rid="B7" ref-type="bibr">King et al., 1998</xref>; <xref rid="B5" ref-type="bibr">Fields et al., 2004</xref>; <xref rid="B25" ref-type="bibr">Yang et al., 2008</xref>; <xref rid="B6" ref-type="bibr">Jin et al., 2014</xref>; <xref rid="B18" ref-type="bibr">Qin, 2014</xref>). These results demonstrated the reliability and capability of OSlihc web server in prognosis analysis.</p>
    <p>The limitation of OSlihc is that only 637 LIHC clinical cases are currently available in OSlihc. When new datasets with profiling and clinical follow-up data become available, we will update the repository of OSlihc server to improve the performance.</p>
    <p>In conclusion, we developed an online prognosis analysis tool named OSlihc, which provides a platform for researchers to discover the new prognostic biomarkers and may offer opportunities to develop novel targeted strategies for LIHC, conducing to clinical translation of potential biomarkers.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>Publicly available datasets were analyzed in this study. This data can be found here: TCGA database (<uri xlink:type="simple" xlink:href="https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga">https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga</uri>) and GEO database (<uri xlink:type="simple" xlink:href="https://www.ncbi.nlm.nih.gov/gds/?term">https://www.ncbi.nlm.nih.gov/gds/?term</uri>=).</p>
  </sec>
  <sec id="s6">
    <title>Author Contributions</title>
    <p>YA, QW, and XG developed the server, performed the evaluation of novel prognostic biomarkers and drafted the paper. GZ, LZ, and FS performed the validation of previous reported biomarkers. HL, YL, and YP collected LIHC datasets. WZ and SJ contributed to data analysis and paper revision. All authors contributed to the article and approved the submitted version.</p>
  </sec>
  <sec sec-type="funding-information" id="s7">
    <title>Funding</title>
    <p>This study is supported by National Natural Science Foundation of China (No.81602362), Supporting grants of Henan University (No.2015YBZR048, No.B2015151, No.2019YLXKJC04), Yellow River Scholar Program (No.H2016012), and Program for Innovative Talents of Science and Technology in Henan Province (No. 18HASTIT048), Program for Science and Technology Development in Henan Province (No.162102310391, No.172102210187), Program for Scientific and Technological Research of Henan Education Department (No.14B520022), Program for Young Key Teacher of Henan Province (No.2016GGJS-214), Kaifeng Science and Technology Major Project (No.18ZD008), Supporting grant of Bioinformatics Center of Henan University (No.2018YLJC01), and Innovation Project for College Students of Henan University (No.2019101904). All the funding sources have roles in study design, data collection, data analysis, and paper writing.</p>
  </sec>
  <sec id="s8">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
</body>
<back>
  <sec sec-type="supplementary-material" id="s9">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2020.00875/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2020.00875/full#supplementary-material</ext-link></p>
    <supplementary-material content-type="local-data" id="SF1">
      <label>Figure S1</label>
      <caption>
        <p>Screenshot of OSlihc subfield interface. <bold>(A)</bold> TCGA, <bold>(B)</bold> GSE20140, <bold>(C)</bold> GSE76427 dataset (using BCLC stage as an example).</p>
      </caption>
      <media xlink:href="Image_1.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SF2">
      <label>Figure S2</label>
      <caption>
        <p>Validation of the top three high-frequency reported biomarkers in OSlihc. Kaplan–Meier plots for <bold>(A–C)</bold>
<italic>SPP1</italic>, <bold>(D–F)</bold>
<italic>MKI67</italic>, and <bold>(G–I)</bold>
<italic>BIRC5</italic> in terms of DSS, DFI and PFI.</p>
      </caption>
      <media xlink:href="Image_2.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SF3">
      <label>Figure S3</label>
      <caption>
        <p>Gene expression analysis of <italic>SPP1</italic>
<bold>(A)</bold>, <italic>MKI67</italic>
<bold>(B)</bold> and <italic>BIRC5</italic>
<bold>(C)</bold> at GEPIA with comparison between tumor and normal tissues.</p>
      </caption>
      <media xlink:href="Image_3.tif">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="ST1">
      <label>Table S1</label>
      <caption>
        <p>Clinicopathologic Characteristics of LIHC patients in TCGA dataset.</p>
      </caption>
      <media xlink:href="Table_1.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="ST2">
      <label>Table S2</label>
      <caption>
        <p>Clinicopathologic Characteristics of LIHC patients in GEO datasets.</p>
      </caption>
      <media xlink:href="Table_2.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="ST3">
      <label>Table S3</label>
      <caption>
        <p>Validation of previously published predictors for LIHC survival in OSlihc.</p>
      </caption>
      <media xlink:href="Table_3.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="ST4">
      <label>Table S4</label>
      <caption>
        <p>Identification of novel potential prognostic biomarkers for LIHC in OSlihc.</p>
      </caption>
      <media xlink:href="Table_4.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buonaguro</surname><given-names>L.</given-names></name><name><surname>Tagliamonte</surname><given-names>M.</given-names></name><name><surname>Petrizzo</surname><given-names>A.</given-names></name><name><surname>Damiano</surname><given-names>E.</given-names></name><name><surname>Tornesello</surname><given-names>M. L.</given-names></name><name><surname>Buonaguro</surname><given-names>F. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Cellular prognostic markers in hepatocellular carcinoma</article-title>. <source>Future Oncol.</source>
<volume>11</volume> (<issue>11</issue>), <fpage>1591</fpage>–<lpage>1598</lpage>.  <pub-id pub-id-type="doi">10.2217/fon.15.39</pub-id>
<pub-id pub-id-type="pmid">26043213</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrero-de Las Heras</surname><given-names>S.</given-names></name><name><surname>Martinez-Balibrea</surname><given-names>E.</given-names></name></person-group> (<year>2018</year>). <article-title>CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer</article-title>. <source>World J. Gastroenterol.</source>
<volume>24</volume> (<issue>42</issue>), <fpage>4738</fpage>–<lpage>4749</lpage>.  <pub-id pub-id-type="doi">10.3748/wjg.v24.i42.4738</pub-id>
<pub-id pub-id-type="pmid">30479461</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristea</surname><given-names>C. G.</given-names></name><name><surname>Gheonea</surname><given-names>I. A.</given-names></name><name><surname>Sandulescu</surname><given-names>L. D.</given-names></name><name><surname>Gheonea</surname><given-names>D. I.</given-names></name><name><surname>Ciurea</surname><given-names>T.</given-names></name><name><surname>Purcarea</surname><given-names>M. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma</article-title>. <source>J. Med. Life</source>
<volume>8</volume> (<issue>2</issue>), <fpage>120</fpage>–<lpage>128</lpage>.
<pub-id pub-id-type="pmid">25866565</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Arcangelo</surname><given-names>D.</given-names></name><name><surname>Giampietri</surname><given-names>C.</given-names></name><name><surname>Muscio</surname><given-names>M.</given-names></name><name><surname>Scatozza</surname><given-names>F.</given-names></name><name><surname>Facchiano</surname><given-names>F.</given-names></name><name><surname>Facchiano</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>WIPI1, BAG1, and PEX3 Autophagy-Related Genes Are Relevant Melanoma Markers</article-title>. <source>Oxid. Med. Cell Longev.</source>
<volume>2018</volume>, <elocation-id>1471682</elocation-id>.  <pub-id pub-id-type="doi">10.1155/2018/1471682</pub-id>
<pub-id pub-id-type="pmid">30622661</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fields</surname><given-names>A. C.</given-names></name><name><surname>Cotsonis</surname><given-names>G.</given-names></name><name><surname>Sexton</surname><given-names>D.</given-names></name><name><surname>Santoianni</surname><given-names>R.</given-names></name><name><surname>Cohen</surname><given-names>C.</given-names></name></person-group> (<year>2004</year>). <article-title>Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome</article-title>. <source>Mod. Pathol.</source>
<volume>17</volume> (<issue>11</issue>), <fpage>1378</fpage>–<lpage>1385</lpage>.  <pub-id pub-id-type="doi">10.1038/modpathol.3800203</pub-id>
<pub-id pub-id-type="pmid">15195112</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J. N.</given-names></name><name><surname>Feng</surname><given-names>Z. Y.</given-names></name><name><surname>Zhang</surname><given-names>Z. G.</given-names></name><name><surname>Fan</surname><given-names>W. Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>OPN and alphavbeta3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma</article-title>. <source>PloS One</source>
<volume>9</volume> (<issue>2</issue>), <elocation-id>e87930</elocation-id>.  <pub-id pub-id-type="doi">10.1371/journal.pone.0087930</pub-id>
<pub-id pub-id-type="pmid">24498405</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>K. L.</given-names></name><name><surname>Hwang</surname><given-names>J. J.</given-names></name><name><surname>Chau</surname><given-names>G. Y.</given-names></name><name><surname>Tsay</surname><given-names>S. H.</given-names></name><name><surname>Chi</surname><given-names>C. W.</given-names></name><name><surname>Lee</surname><given-names>T. G.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma</article-title>. <source>J. Gastroenterol. Hepatol.</source>
<volume>13</volume> (<issue>3</issue>), <fpage>273</fpage>–<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1746.1998.01555.x</pub-id>
<pub-id pub-id-type="pmid">9570240</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>le Rolle</surname><given-names>A. F.</given-names></name><name><surname>Chiu</surname><given-names>T. K.</given-names></name><name><surname>Fara</surname><given-names>M.</given-names></name><name><surname>Shia</surname><given-names>J.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Weiser</surname><given-names>M. R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts</article-title>. <source>J. Transl. Med.</source>
<volume>13</volume>, <fpage>199</fpage>.  <pub-id pub-id-type="doi">10.1186/s12967-015-0555-4</pub-id>
<pub-id pub-id-type="pmid">26104296</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y. K.</given-names></name><name><surname>Kim</surname><given-names>S. U.</given-names></name><name><surname>Kim</surname><given-names>D. Y.</given-names></name><name><surname>Ahn</surname><given-names>S. H.</given-names></name><name><surname>Lee</surname><given-names>K. H.</given-names></name><name><surname>Lee</surname><given-names>D. Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization</article-title>. <source>BMC Cancer</source>
<volume>13</volume>, <fpage>5</fpage>.  <pub-id pub-id-type="doi">10.1186/1471-2407-13-5</pub-id>
<pub-id pub-id-type="pmid">23282286</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Rhim</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Kang</surname><given-names>T. W.</given-names></name><name><surname>Song</surname><given-names>K. D.</given-names></name></person-group> (<year>2016</year>). <article-title>Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma</article-title>. <source>Liver</source>
<volume>36</volume> (<issue>4</issue>), <fpage>580</fpage>–<lpage>587</lpage>.  <pub-id pub-id-type="doi">10.1111/liv.12991</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J. C.</given-names></name><name><surname>Wu</surname><given-names>Y. C.</given-names></name><name><surname>Wu</surname><given-names>C. C.</given-names></name><name><surname>Shih</surname><given-names>P. Y.</given-names></name><name><surname>Wang</surname><given-names>W. Y.</given-names></name><name><surname>Chien</surname><given-names>Y. C.</given-names></name></person-group> (<year>2015</year>). <article-title>DNA methylation markers and serum alpha-fetoprotein level are prognostic factors in hepatocellular carcinoma</article-title>. <source>Ann. hepatology.</source>
<volume>14</volume> (<issue>4</issue>), <fpage>494</fpage>–<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1016/S1665-2681(19)31171-8</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lichtenberg</surname><given-names>T.</given-names></name><name><surname>Hoadley</surname><given-names>K. A.</given-names></name><name><surname>Poisson</surname><given-names>L. M.</given-names></name><name><surname>Lazar</surname><given-names>A. J.</given-names></name><name><surname>Cherniack</surname><given-names>A. D.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics</article-title>. <source>Cell</source>
<volume>173</volume> (<issue>2</issue>), <fpage>400</fpage>–<lpage>16 e11</lpage>.  <pub-id pub-id-type="doi">10.1016/j.cell.2018.02.052</pub-id>
<pub-id pub-id-type="pmid">29625055</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma</article-title>. <source>Tumour Biol.</source>
<volume>37</volume> (<issue>6</issue>), <fpage>7405</fpage>–<lpage>7412</lpage>.  <pub-id pub-id-type="doi">10.1007/s13277-015-4582-9</pub-id>
<pub-id pub-id-type="pmid">26676639</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullath</surname><given-names>A.</given-names></name><name><surname>Krishna</surname><given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Hepatocellular carcinoma - time to take the ticket</article-title>. <source>World J. Gastrointest. Surg.</source>
<volume>11</volume> (<issue>6</issue>), <fpage>287</fpage>–<lpage>295</lpage>.  <pub-id pub-id-type="doi">10.4240/wjgs.v11.i6.287</pub-id>
<pub-id pub-id-type="pmid">31367276</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>M.</given-names></name><name><surname>Matsui</surname><given-names>Y.</given-names></name><name><surname>Kobayashi</surname><given-names>T.</given-names></name><name><surname>Saito</surname><given-names>R.</given-names></name><name><surname>Hatahira</surname><given-names>S.</given-names></name><name><surname>Kawakami</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer</article-title>. <source>Cancer Biomark.</source>
<volume>15</volume> (<issue>4</issue>), <fpage>357</fpage>–<lpage>364</lpage>.  <pub-id pub-id-type="doi">10.3233/CBM-150472</pub-id>
<pub-id pub-id-type="pmid">26406865</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>dbPHCC: a database of prognostic biomarkers for hepatocellular carcinoma that provides online prognostic modeling</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1860</volume> (<issue>11 Pt B</issue>), <fpage>2688</fpage>–<lpage>2695</lpage>.  <pub-id pub-id-type="doi">10.1016/j.bbagen.2016.02.017</pub-id>
<pub-id pub-id-type="pmid">26940364</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinato</surname><given-names>D. J.</given-names></name><name><surname>Pirisi</surname><given-names>M.</given-names></name><name><surname>Maslen</surname><given-names>L.</given-names></name><name><surname>Sharma</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Tissue biomarkers of prognostic significance in hepatocellular carcinoma</article-title>. <source>Adv. Anat. Pathol.</source>
<volume>21</volume> (<issue>4</issue>), <fpage>270</fpage>–<lpage>284</lpage>.  <pub-id pub-id-type="doi">10.1097/PAP.0000000000000029</pub-id>
<pub-id pub-id-type="pmid">24911252</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies</article-title>. <source>Front. Med.</source>
<volume>8</volume> (<issue>1</issue>), <fpage>24</fpage>–<lpage>32</lpage>.  <pub-id pub-id-type="doi">10.1007/s11684-014-0312-8</pub-id>
<pub-id pub-id-type="pmid">24464486</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selcuk</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>Prognostic Factors and Staging Systems in Hepatocellular Carcinoma</article-title>. <source>Exp. Clin. Transplant.</source>
<volume>15</volume> (<issue>Suppl 2</issue>), <fpage>45</fpage>–<lpage>49</lpage>.  <pub-id pub-id-type="doi">10.6002/ect.TOND16.L11</pub-id>
<pub-id pub-id-type="pmid">28301998</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J. Y.</given-names></name><name><surname>Hsi</surname><given-names>E.</given-names></name><name><surname>Huang</surname><given-names>Y. C.</given-names></name><name><surname>Hsu</surname><given-names>N. C.</given-names></name><name><surname>Chen</surname><given-names>Y. K.</given-names></name><name><surname>Chu</surname><given-names>P. Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>ATG9A overexpression is associated with disease recurrence and poor survival in patients with oral squamous cell carcinoma</article-title>. <source>Virchows Arch.</source>
<volume>463</volume> (<issue>6</issue>), <fpage>737</fpage>–<lpage>742</lpage>.  <pub-id pub-id-type="doi">10.1007/s00428-013-1482-5</pub-id>
<pub-id pub-id-type="pmid">24085552</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>CXCL1 gene silencing inhibits HGC803 cell migration and invasion and acts as an independent prognostic factor for poor survival in gastric cancer</article-title>. <source>Mol. Med. Rep.</source>
<volume>14</volume> (<issue>5</issue>), <fpage>4673</fpage>–<lpage>4679</lpage>.  <pub-id pub-id-type="doi">10.3892/mmr.2016.5843</pub-id>
<pub-id pub-id-type="pmid">27748927</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Xin</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2019</year>a). <article-title>Interactive online consensus survival tool for esophageal squamous cell carcinoma prognosis analysis</article-title>. <source>Oncol. Lett.</source>
<volume>18</volume> (<issue>2</issue>), <fpage>1199</fpage>–<lpage>1206</lpage>.  <pub-id pub-id-type="doi">10.3892/ol.2019.10440</pub-id>
<pub-id pub-id-type="pmid">31423180</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Dang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>T.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019</year>b). <article-title>OSlms: A Web Server to Evaluate the Prognostic Value of Genes in Leiomyosarcoma</article-title>. <source>Front. Oncol.</source>
<volume>9</volume>, <elocation-id>190</elocation-id>.  <pub-id pub-id-type="doi">10.3389/fonc.2019.00190</pub-id>
<pub-id pub-id-type="pmid">30984618</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Dang</surname><given-names>Y.</given-names></name><name><surname>Ge</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>OSkirc: a web tool for identifying prognostic biomarkers in kidney renal clear cell carcinoma</article-title>. <source>Future Oncol.</source>
<volume>15</volume> (<issue>27</issue>), <fpage>3103</fpage>–<lpage>3110</lpage>.  <pub-id pub-id-type="doi">10.2217/fon-2019-0296</pub-id>
<pub-id pub-id-type="pmid">31368353</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>G. H.</given-names></name><name><surname>Fan</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Qiu</surname><given-names>S. J.</given-names></name><name><surname>Yang</surname><given-names>X. R.</given-names></name><name><surname>Shi</surname><given-names>G. M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection</article-title>. <source>Oncologist</source>
<volume>13</volume> (<issue>11</issue>), <fpage>1155</fpage>–<lpage>1165</lpage>.  <pub-id pub-id-type="doi">10.1634/theoncologist.2008-0081</pub-id>
<pub-id pub-id-type="pmid">18997126</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>M.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma</article-title>. <source>Oncotarget</source>
<volume>7</volume> (<issue>4</issue>), <fpage>3702</fpage>–<lpage>3708</lpage>.  <pub-id pub-id-type="doi">10.18632/oncotarget.6913</pub-id>
<pub-id pub-id-type="pmid">26784252</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Xue</surname><given-names>H.</given-names></name><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Resveratrol Inhibits Invasion and Metastasis of Hepatocellular Carcinoma Cells</article-title>. <source>J. Anim. Vet. Adv.</source>
<volume>9</volume> (<issue>24</issue>), <fpage>3117</fpage>–<lpage>3124</lpage>. <pub-id pub-id-type="doi">10.3923/javaa.2010.3117.3124</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Yuan</surname><given-names>Q.</given-names></name><name><surname>Dang</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients</article-title>. <source>Front. Oncol.</source>
<volume>9</volume>, <elocation-id>466</elocation-id>.  <pub-id pub-id-type="doi">10.3389/fonc.2019.00466</pub-id>
<pub-id pub-id-type="pmid">31275847</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuo</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>D.</given-names></name><name><surname>Jian</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer</article-title>. <source>Biosci. Rep.</source>
<volume>38</volume> (<issue>4</issue>), <elocation-id>BSR20180580</elocation-id>.  <pub-id pub-id-type="doi">10.1042/BSR20180580</pub-id>
<pub-id pub-id-type="pmid">29784873</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>A.</given-names></name><name><surname>Lambert</surname><given-names>D.</given-names></name><name><surname>Yeh</surname><given-names>H.</given-names></name><name><surname>Yasukawa</surname><given-names>K.</given-names></name><name><surname>Behbod</surname><given-names>F.</given-names></name><name><surname>Fan</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-beta signaling proteins</article-title>. <source>BMC Cancer</source>
<volume>14</volume>, <fpage>781</fpage>.  <pub-id pub-id-type="doi">10.1186/1471-2407-14-781</pub-id>
<pub-id pub-id-type="pmid">25344051</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
